Press releases
- Charles River Laboratories Schedules Second-Quarter 2024 Earnings Release and Conference Call
- Charles River to Perform Plasmid Manufacturing for AAVantgarde
- Charles River Laboratories Announces Strategic Lentiviral Vector Manufacturing Collaboration with Gates Institute at University of Colorado Anschutz Medical Campus
- Charles River and Captain T Cell Announce Plasmid DNA and Viral Vector Manufacturing Alliance for Gene-Modified Cell Therapy
- Charles River Laboratories, in Collaboration With MatTek Corporation, Awarded Grant from the Foundation for Chemistry Research and Initiatives to Advance Research Alternatives
- Charles River Laboratories Expands Access to CRADL® Contract Vivarium Space in Somerville
- Charles River Laboratories Announces Development of Nonclinical Virtual Control Groups with Sanofi to Reduce the Use of Animals in Research
- Charles River Laboratories to Present at William Blair and Jefferies Conferences
- Charles River Launches Viral Vector Tech Transfer Program to Safeguard Gene Therapy Development
- Charles River Laboratories Announces First-Quarter 2024 Results
More ▼
Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | -- |
Average volume | -- |
---|---|
Shares outstanding | 51.51m |
Free float | 51.00m |
P/E (TTM) | 26.18 |
Market cap | 11.49bn USD |
EPS (TTM) | 8.52 USD |
Data delayed at least 15 minutes.
More ▼